LRMR on Nasdaq

Zafgen (United States)

American pharmaceutical preparations company based in Boston, founded in 2005.¹

Price unavailable

Last updated Oct 18, 2026.

Overview

2005Founded¹

Compare with another stock.

TickerLRMR on Nasdaq¹
IndustryPharmaceutical Preparations¹
HeadquartersBoston¹
Websitewww.zafgen.com
Legal formDelaware corporation¹
Incorporated inDE³
Business addressThree Bala Plaza East. Suite 506, Bala Cynwyd, Pa 19004³
Filer categoryNon-accelerated filer, Smaller reporting company³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2019

-$22.8MFree cash flow⁴

Financial statements

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁸

Period ending	2025-12-31	2024-12-31
Research and development	$154.2M	$73.3M
General and administrative	$18.3M	$17.6M
Total operating expenses	$172.5M	$90.9M
Loss from operations	-$172.5M	-$90.9M
Other income, net	$6.8M	$10.3M
Net loss	-$165.7M	-$80.6M
Unrealized gain (loss) on marketable securities	-$94.0K	$67.0K
Total other comprehensive gain (loss)	-$94.0K	$67.0K
Total comprehensive loss	-$165.8M	-$80.5M

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.⁸

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$85.4M	$33.2M
Short-term marketable securities	$51.4M	$150.2M
Prepaid expenses and other current assets	$5.2M	$11.8M
Total current assets	$142.0M	$195.3M
Property and equipment, net	$622.0K	$881.0K
Operating lease right-of-use assets	$2.1M	$2.8M
Restricted cash	$606.0K	$606.0K
Other assets	$523.0K	$596.0K
Total assets	$145.8M	$200.2M
Accounts payable	$5.2M	$2.4M
Accrued expenses	$58.5M	$20.9M
Operating lease liabilities, current	$1.1M	$1.1M
Total current liabilities	$64.8M	$24.4M
Operating lease liabilities	$3.0M	$4.1M
Total liabilities	$67.8M	$28.4M
Common stock, $0.001 par value per share; 115,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 83,090,392 and 63,815,065 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	$83.0K	$64.0K
Additional paid-in capital	$512.8M	$440.8M
Accumulated deficit	-$434.8M	-$269.2M
Accumulated other comprehensive gain	$54.0K	$148.0K
Total stockholders' equity	$78.1M	$171.8M	$81.7M
Total liabilities and stockholders' equity	$145.8M	$200.2M
Preferred stock, par value per share	$0.00	$0.00
Preferred stock, shares authorized	5.0M shares	5.0M shares
Preferred stock, shares issued	250.0K shares	0 shares
Preferred stock, shares outstanding	250.0K shares	0 shares
Common stock, par value per share	$0.00	$0.00
Common stock, shares authorized	115.0M shares	115.0M shares
Common stock, shares issued	83.1M shares	63.8M shares
Common stock, shares outstanding	83.1M shares	63.8M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$85.4M	$33.2M
Short-term marketable securities	$51.4M	$150.2M
Prepaid expenses and other current assets	$5.2M	$11.8M
Total current assets	$142.0M	$195.3M
Property and equipment, net	$622.0K	$881.0K
Operating lease right-of-use assets	$2.1M	$2.8M
Restricted cash	$606.0K	$606.0K
Other assets	$523.0K	$596.0K
Total assets	$145.8M	$200.2M
Accounts payable	$5.2M	$2.4M
Accrued expenses	$58.5M	$20.9M
Operating lease liabilities, current	$1.1M	$1.1M
Total current liabilities	$64.8M	$24.4M
Operating lease liabilities	$3.0M	$4.1M
Total liabilities	$67.8M	$28.4M
Common stock, $0.001 par value per share; 115,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 83,090,392 and 63,815,065 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	$83.0K	$64.0K
Additional paid-in capital	$512.8M	$440.8M
Accumulated deficit	-$434.8M	-$269.2M
Accumulated other comprehensive gain	$54.0K	$148.0K
Total stockholders' equity	$78.1M	$171.8M	$81.7M
Total liabilities and stockholders' equity	$145.8M	$200.2M
Preferred stock, par value per share	$0.00	$0.00
Preferred stock, shares authorized	5.0M shares	5.0M shares
Preferred stock, shares issued	250.0K shares	0 shares
Preferred stock, shares outstanding	250.0K shares	0 shares
Common stock, par value per share	$0.00	$0.00
Common stock, shares authorized	115.0M shares	115.0M shares
Common stock, shares issued	83.1M shares	63.8M shares
Common stock, shares outstanding	83.1M shares	63.8M shares

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁸

Period ending	2025-12-31	2024-12-31
Net loss	-$165.7M	-$80.6M
Stock-based compensation expense	$7.0M	$8.8M
Lease expense	-$281.0K	-$189.0K
Depreciation expense	$350.0K	$318.0K
Amortization of premium on marketable securities	-$1.7M	-$5.3M
Prepaid expenses and other current assets	$6.7M	-$8.5M
Accounts payable	$2.8M	$1.1M
Accrued expenses	$37.6M	$13.4M
Other assets	$73.0K	$63.0K
Net cash used in operating activities	-$113.2M	-$70.8M
Purchases of property and equipment	-$91.0K	-$515.0K
Purchases of marketable securities	-$83.6M	-$227.9M
Maturities of marketable securities	$184.0M	$143.0M
Net cash provided by (used in) investing activities	$100.3M	-$85.4M
Proceeds from issuance of common stock, net of issuance costs	$65.1M	$161.8M
Proceeds from exercise of stock options and warrants		$77.0K
Net cash provided by financing activities	$65.1M	$161.9M
Net increase in cash, cash equivalents and restricted cash	$52.2M	$5.7M
Offering costs included in accounts payable and accrued expense	$100.0K	$50.0K
Leased assets obtained in exchange for new operating lease liabilities		$465.0K

Compare Zafgen (United States) with another company

Leadership

Who has led Zafgen (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chief financial officer

2010201520202025

Chief executive officerJeffrey S. Hatfield Oct 11, 2017 to Jan 24, 2019¹⁰
Chief executive officerThomas E. Hughes Jun 18, 2014 to May 15, 2017¹¹
PresidentThomas E. Hughes Jul 26, 2016 to May 15, 2017¹²
PresidentPatrick Loustau Jun 18, 2014 to Apr 4, 2016¹³
Chief financial officerMichael Celano Jun 5, 2020 to now¹⁴
Chief financial officerPatricia L. Allen Mar 3, 2015 to Jan 24, 2019¹⁵

Board members and other officers (28)

Chief Development OfficerGopi Shankar Feb 9, 2023 to now¹⁶
Chief Medical OfficerRussell Clayton Jul 18, 2023 to now¹⁷
OfficerPriya Singhal Mar 11, 2019 to Apr 4, 2019¹⁸
Chief Business OfficerBrian McVeigh May 30, 2018 to Jan 24, 2019¹⁹
OfficerThomas E. Hughes Oct 11, 2017 to Jun 29, 2018²⁰
Chief Commercial OfficerAlicia Secor Jun 18, 2014 to Apr 4, 2016²¹
Chief Medical OfficerDennis D. Kim Jun 18, 2014 to Jan 24, 2019²²
OfficerPatricia L. Allen Jun 18, 2014 to Jun 18, 2014²³
Board memberJeffrey W. Sherman Oct 5, 2023 to now²⁴
Board memberJonathan S. Leff Jun 5, 2020 to now²⁵
Board memberJoseph Truitt Jun 5, 2020 to now²⁶
Board memberThomas Edward Hamilton Jun 5, 2020 to now²⁷
Board memberJames E. Flynn Jun 8, 2020 to now²⁸
Board memberMgmt Hif L.p. Deerfield Jun 8, 2020 to now²⁸
Board memberMgmt L.p. Deerfield Iv. Jun 8, 2020 to now²⁸
Board memberWendy Everett Jun 7, 2018 to Jun 27, 2019²⁹
Board memberJeffrey S. Hatfield Oct 11, 2017 to Jan 24, 2019¹⁰
Board memberThomas O. Daniel Mar 10, 2016 to May 17, 2021³⁰
Board memberCameron Geoffrey McDonough Sep 28, 2015 to Jun 27, 2019³¹
Board memberRobert J. Perez Sep 28, 2015 to Jun 27, 2019³²
Board memberAvi Y. Goldberg Jun 18, 2014 to Sep 21, 2015³³
Board memberBruce Booth Jun 18, 2014 to Jan 5, 2018³⁴
Board memberFrank E. Thomas Jun 18, 2014 to now³⁵
Board memberJohn L. Lamattina Jun 18, 2014 to Jun 27, 2019³⁶
Board memberKevin P. Starr Jun 18, 2014 to Sep 25, 2015³⁷
Board memberPeter Barrett Jun 18, 2014 to May 12, 2022³⁸
Board memberThomas E. Hughes Jun 18, 2014 to Jun 29, 2018¹¹
Board memberFrances K. Heller Sep 18, 2014 to Oct 17, 2017³⁹

Former names

ZAFGEN, INC.Mar 1, 2010 to May 19, 2020³
ZAFGEN INCAug 28, 2006 to Nov 3, 2008³

Timeline

Oct 11, 2017New chief executive Jeffrey S. Hatfield becomes CEO¹⁰
Jun 18, 2014New chief executive Thomas E. Hughes becomes CEO¹¹
2005Founded Founded¹

Filings

229 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 66 major events, 72 insider forms, 38 large holders, 33 other. The latest 20:

Oct 1, 20264 EDGAR
Oct 1, 20263 EDGAR
Sep 29, 20268-K EDGAR
Aug 4, 202610-Q EDGAR
Aug 4, 20268-K EDGAR
Jul 8, 20264 EDGAR
Jun 29, 20268-K EDGAR
May 20, 20264 EDGAR
May 20, 20264 EDGAR
May 20, 20264 EDGAR
May 20, 20264 EDGAR
May 20, 20264 EDGAR
May 20, 20264 EDGAR
May 19, 20268-K EDGAR
May 14, 202610-Q EDGAR
May 14, 20268-K EDGAR
May 14, 2026SCHEDULE 13G/A EDGAR
Apr 30, 2026SCHEDULE 13G/A EDGAR
Apr 20, 2026ARS EDGAR
Apr 20, 2026DEF 14A EDGAR

The 229 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 38 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Deerfield Management Company, L.P.	35,606,974	$108.6M	1.4%	No change
Blue Owl Capital Holdings LP	9,163,157	$27.9M	4.2%	+2,043,150
BlackRock, Inc.	5,678,035	$17.3M	0.0%	+1,925,835
Defilade Capital Management, L.P.	3,670,135	$11.2M	1.5%	New
Driehaus Capital Management LLC	3,163,423	$9.6M	0.1%	+229,024
Vanguard Capital Management LLC	2,974,901	$9.1M	0.0%	+108,552
Rtw Investments, LP	2,565,999	$7.8M	0.1%	+1,065,999
Aqr Capital Management LLC	2,371,414	$7.2M	0.0%	+1,553,897
Marshall Wace, Llp	2,012,458	$6.1M	0.0%	+1,078,994
DAFNA Capital Management LLC	2,008,164	$6.1M	1.2%	−21,000
Goldman Sachs Group Inc	1,752,910	$5.3M	0.0%	+191,325
Geode Capital Management, LLC	1,679,003	$5.1M	0.0%	+570,242
Qube Research & Technologies Ltd	1,641,042	$5.0M	0.0%	+793,398
Citadel Advisors LLC	1,456,825	$4.4M	0.0%	+937,693
State Street Corp	1,411,804	$4.3M	0.0%	+500,478
Vanguard Portfolio Management LLC	1,403,172	$4.3M	0.0%	+996,614
Woodline Partners LP	1,400,850	$4.3M	0.0%	No change
Millennium Management LLC	1,333,037	$4.1M	0.0%	−2,292,241
Dimensional Fund Advisors LP	961,083	$2.9M	0.0%	+162,621
Fmr LLC	937,368	$2.9M	0.0%	+873,798
Sphera Funds Management Ltd.	926,004	$2.8M	0.4%	New
Nuveen, LLC	895,304	$2.7M	0.0%	+220,389
Alyeska Investment Group, L.P.	617,211	$1.9M	0.0%	No change
Northern Trust Corp	550,266	$1.7M	0.0%	+173,763
Vanguard Fiduciary Trust Co	448,168	$1.4M	0.0%	+158,536

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataZafgen (United States) on Wikidata
2
SEC EDGARZafgen (United States) filings on SEC EDGAR
3
SEC EDGARZafgen (United States) filings on SEC EDGAR
4
SEC EDGARZafgen (United States) 10-K for fiscal 2019
5
SEC EDGARZafgen (United States) 10-K for fiscal 2019
6
SEC EDGARZafgen (United States) 10-Q for fiscal 2026
7
SEC EDGARZafgen (United States) 10-Q for fiscal 2026
8
SEC EDGARZafgen (United States) 10-K filed 2026-03-19: income statement
9
SEC EDGARZafgen (United States) 10-K for fiscal 2019
10
SEC EDGARJeffrey S. Hatfield, Chief executive officer
11
SEC EDGARThomas E. Hughes, Chief executive officer
12
SEC EDGARThomas E. Hughes, President
13
SEC EDGARPatrick Loustau, President
14
SEC EDGARMichael Celano, Chief financial officer
15
SEC EDGARPatricia L. Allen, Chief financial officer
16
SEC EDGARGopi Shankar, Chief Development Officer
17
SEC EDGARRussell Clayton, Chief Medical Officer
18
SEC EDGARPriya Singhal, Officer
19
SEC EDGARBrian McVeigh, Chief Business Officer
20
SEC EDGARThomas E. Hughes, Officer
21
SEC EDGARAlicia Secor, Chief Commercial Officer
22
SEC EDGARDennis D. Kim, Chief Medical Officer
23
SEC EDGARPatricia L. Allen, Officer
24
SEC EDGARJeffrey W. Sherman, Board member
25
SEC EDGARJonathan S. Leff, Board member
26
SEC EDGARJoseph Truitt, Board member
27
SEC EDGARThomas Edward Hamilton, Board member
28
SEC EDGARJames E. Flynn, Board member
29
SEC EDGARWendy Everett, Board member
30
SEC EDGARThomas O. Daniel, Board member
31
SEC EDGARCameron Geoffrey McDonough, Board member
32
SEC EDGARRobert J. Perez, Board member
33
SEC EDGARAvi Y. Goldberg, Board member
34
SEC EDGARBruce Booth, Board member
35
SEC EDGARFrank E. Thomas, Board member
36
SEC EDGARJohn L. Lamattina, Board member
37
SEC EDGARKevin P. Starr, Board member
38
SEC EDGARPeter Barrett, Board member
39
SEC EDGARFrances K. Heller, Board member